Renaissance Technologies’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-205,961
| Closed | -$2.7M | – | 3249 |
|
|
2025
Q4 | $2.7M | Sell |
205,961
-189,300
| -48% | -$2.26M | ﹤0.01% | 1683 |
|
|
2025
Q3 | $2.88M | Buy |
395,261
+105,483
| +36% | +$714K | ﹤0.01% | 1832 |
|
|
2025
Q2 | $1.55M | Buy |
289,778
+110,617
| +62% | +$536K | ﹤0.01% | 2267 |
|
|
2025
Q1 | $957K | Buy |
+179,161
| New | +$1.25M | ﹤0.01% | 2454 |
|
|
2024
Q4 | – | Sell |
-38,061
| Closed | -$419K | – | 3562 |
|
|
2024
Q3 | $419K | Buy |
38,061
+15,600
| +69% | +$173K | ﹤0.01% | 2861 |
|
|
2024
Q2 | $204K | Sell |
22,461
-18,939
| -46% | -$185K | ﹤0.01% | 3042 |
|
|
2024
Q1 | $583K | Buy |
41,400
+27,200
| +192% | +$339K | ﹤0.01% | 2798 |
|
|
2023
Q4 | $109K | Buy |
14,200
+4,100
| +41% | +$22.7K | ﹤0.01% | 3286 |
|
|
2023
Q3 | $75K | Sell |
10,100
-80,961
| -89% | -$690K | ﹤0.01% | 3305 |
|
|
2023
Q2 | $759K | Buy |
91,061
+42,761
| +89% | +$493K | ﹤0.01% | 2642 |
|
|
2023
Q1 | $642K | Sell |
48,300
-33,961
| -41% | -$459K | ﹤0.01% | 2742 |
|
|
2022
Q4 | $1.23M | Buy |
82,261
+24,400
| +42% | +$252K | ﹤0.01% | 2408 |
|
|
2022
Q3 | $523K | Buy |
57,861
+44,161
| +322% | +$296K | ﹤0.01% | 2905 |
|
|
2022
Q2 | $41K | Buy |
+13,700
| New | +$61.4K | ﹤0.01% | 4025 |
|
|
2022
Q1 | – | Sell |
-34,361
| Closed | -$185K | – | 4067 |
|
|
2021
Q4 | $185K | Sell |
34,361
-74,992
| -69% | -$493K | ﹤0.01% | 3538 |
|
|
2021
Q3 | $967K | Buy |
109,353
+46,443
| +74% | +$445K | ﹤0.01% | 2571 |
|
|
2021
Q2 | $796K | Buy |
62,910
+33,067
| +111% | +$429K | ﹤0.01% | 2777 |
|
|
2021
Q1 | $517K | Buy |
+29,843
| New | +$539K | ﹤0.01% | 2895 |
|
|
2020
Q3 | – | Sell |
-17,341
| Closed | -$669K | – | 3364 |
|
|
2020
Q2 | $669K | Buy |
17,341
+7,953
| +85% | +$283K | ﹤0.01% | 2755 |
|
|
2020
Q1 | $234K | Sell |
9,388
-5,886
| -39% | -$182K | ﹤0.01% | 3057 |
|
|
2019
Q4 | $542K | Buy |
15,274
+9,240
| +153% | +$291K | ﹤0.01% | 2873 |
|
|
2019
Q3 | $196K | Sell |
6,034
-5,269
| -47% | -$208K | ﹤0.01% | 3155 |
|
|
2019
Q2 | $547K | Sell |
11,303
-9,391
| -45% | -$426K | ﹤0.01% | 2957 |
|
|
2019
Q1 | $983K | Buy |
20,694
+14,741
| +248% | +$500K | ﹤0.01% | 2674 |
|
|
2018
Q4 | $156K | Sell |
5,953
-1,609
| -21% | -$60.9K | ﹤0.01% | 3178 |
|
|
2018
Q3 | $363K | Sell |
7,562
-6,353
| -46% | -$285K | ﹤0.01% | 2956 |
|
|
2018
Q2 | $801K | Sell |
13,915
-1,955
| -12% | -$180K | ﹤0.01% | 2687 |
|
|
2018
Q1 | $1.72M | Buy |
15,870
+8,058
| +103% | +$806K | ﹤0.01% | 2405 |
|
|
2017
Q4 | $698K | Buy |
7,812
+4,889
| +167% | +$575K | ﹤0.01% | 2802 |
|
|
2017
Q3 | $372K | Buy |
2,923
+1,015
| +53% | +$84.7K | ﹤0.01% | 2858 |
|
|
2017
Q2 | $161K | Buy |
1,908
+806
| +73% | +$67.1K | ﹤0.01% | 3031 |
|
|
2017
Q1 | $106K | Buy |
+1,102
| New | +$152K | ﹤0.01% | 3077 |
|
Renaissance Technologies's ATXS Position: Q1 2026 in Review
Renaissance Technologies sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 205,961 shares — an estimated $2.7M sold.
Renaissance Technologies first reported a position in ATXS in Q1 2017 and held it in 32 quarters. The position peaked at $2.88M in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Renaissance Technologies reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Renaissance Technologies sold 205,961 Astria Therapeutics shares in Q1 2026, an estimated $2.7M.
- Renaissance Technologies first reported a position in Astria Therapeutics in Q1 2017 and held it in 32 quarters.
- Renaissance Technologies's Astria Therapeutics position peaked at $2.88M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.